LONG-ACTING INJECTABLE ANTIPSYCHOTICS: TOOLKIT SUMMARY & FACT SHEET 2017

OUTCOMES:
Used primarily for individuals who struggle with adherence to antipsychotic medication, these medications have been demonstrated through research to help:
- Improve adherence
- Reduce the frequency of symptom relapse
- Reduce re-hospitalization
- Improve treatment outcomes

TOOL KIT:
This toolkit provides information and resources pertaining to long acting injectables (LAIs). The purpose of the toolkit is to support your efforts to provide a seamless transition for your patients from the inpatient setting to the community.

LAI toolkit includes:
- MCO and Pharmacy Benefit Crosswalk
- List of CBH in-network outpatient and CIRC providers that administer LAIs
- LAI Referral and Resource Process Flow
- LAI Webinar Power Point
- LAI Referral Form
- LAI FAQ
- Case Management Referral Form
- Prior Authorization Forms*
- Description of in-home psych nursing service (below)
- Information about care coordination services offered by pharmaceutical companies (below)

*It is important to highlight that each physical health plan in the region has a unique formulary and as such the LAIs on formulary differ slightly amongst plans. The toolkit includes Prior Authorization Forms unique to each plan.

COMMUNITY-BASED SUPPORT THROUGH IN-HOME PSYCHIATRIC NURSING**:
Individuals who are not linked to a LAI-capable case management or outpatient provider and require additional support with community transition can receive visiting psychiatric nursing. In-home psychiatric nursing can help an individual who is prescribed a LAI to:
- Navigate authorization processes for LAI medications
- Assist in obtaining prescription LAIs from physical health plan
- Administer LAI medication for individual on a temporary basis
- Connect individuals with outpatient clinics that can administer LAIs

**Referrals for in-home psychiatric nursing are completed via the LAI and Psychiatric In-Home Nursing Initiation Form found in this toolkit.

CURRENT FDA-APPROVED LAI MEDICATIONS:
- Haldol Decanoate
- Invega Trinza
- Prolixin Decanoate
- Abilify Maintena
- Risperdal Consta
- Abilify Aristada
- Invega Sustenna
- Zyprexa Relprevv

CARE COORDINATION WITH PHARMACEUTICAL COMPANIES:
Certain pharmaceutical companies offer care coordination services; these companies are listed below, with links for further information:
- Abilify Maintena Patient Assistance
- Patient Care Assistance for Invega Trinza, Sustenna & Risperdal Consta
- Aristada Patient Support Program
- Zyprexa Relprevv Patient Care Program

If an individual is in need of additional care coordination services and is prescribed a LAI, this should be brought to the attention of the CBH clinical care manager (CCM) during the course of discharge planning.

LA Definition:
Previously known as depot antipsychotics, long-acting injectable (LAI) antipsychotics are a pharmacologic strategy for treating individuals with schizophrenia who relapse due to non-adherence to oral antipsychotic medication. Unlike their oral counterparts that are taken daily, LAI antipsychotics are administered by injection less frequently, with maintenance doses ranging from every two weeks to every three months. Despite being available for over 45 years, LAI antipsychotics remain an underutilized treatment option for people with serious and persistent mental illness.